YNP 1707Alternative Names: YNP1707
Latest Information Update: 21 Jan 2016
At a glance
- Originator Yungjin Pharm Co
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Neuropathic pain
Most Recent Events
- 21 Jan 2016 Phase-I clinical trials in Neuropathic pain in South Korea (unspecified route) prior to January 2016 (Yungjin Pharm's pipeline, January 2016)